Coronavirus: what is the science behind UK plan to delay second dose of vaccines?
Experts divided over move to broaden gap between the two jabs in order to inoculate more people
Governments and health experts worldwide are considering whether to follow the UK in inoculating as many people as possible against Covid by giving them each just one dose rather than two.
The debate has been raging since the end of December, when Boris Johnson’s government announced plans to postpone giving the second dose of both the Pfizer/BioNTech and the Oxford/AstraZeneca vaccines by up to 12 weeks.
Denmark has now unveiled plans to delay the second dose of both the Pfizer and forthcoming Moderna jabs by up to six weeks, and Germany is considering a similar move.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
But some experts are warning that “delaying could cause further virus mutations and render the shot ineffective”, while others “question whether recipients will be left more vulnerable”, says Politico.
“The only thing that is clear is that a second vaccination is absolutely essential because it triggers the necessary immune response, like a kind of booster,” adds Deutsche Welle.
The World Health Organization has “said it understood why a country facing the sort of increases in cases, hospitalisations and deaths that were happening in the UK might decide to go beyond the evidence” on administration of second doses, The Guardian reports.
But there is “very little empiric data from the trials that underpin this type of recommendation”, said Dr Joachim Hombach of the UN health agency’s strategic advisory group of experts on immunisation.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
According to the newspaper, “there is some evidence from trials of the Oxford/AstraZeneca vaccine that a late second dose, up to 12 weeks, does not interfere with the efficacy of the vaccine”.
But rival vaccine maker Pfizer has said that no data from its own clinical trials was available “to demonstrate that protection after the first dose is sustained after 21 days”.
Despite the misgivings, some experts believe the gains of delaying vaccine doses may outweigh the risks.
Thomas Mertens, from Germany’s public health agency, the Robert Koch Institute, has come out in favour of the UK plan. “Since the interval between the two vaccinations can very likely vary within wide limits and protection is already very good after one shot, it is certainly worth considering giving preference to the first injection in the event of a vaccine shortage,” he said.
The UK’s Joint Committee on Vaccination and Immunisation, an independent body that advises United Kingdom health departments on immunisation, reports that short-term vaccine efficacy from the first dose of the Pfizer-BioNTech vaccine is calculated at around 90%, and at around 70% for the AstraZeneca vaccine.
Given those high levels of protection, “models suggest that initially vaccinating a greater number of people with a single dose will prevent more deaths and hospitalisations than vaccinating a smaller number of people with two doses”, the committee’s experts argue.
Chas Newkey-Burden has been part of The Week Digital team for more than a decade and a journalist for 25 years, starting out on the irreverent football weekly 90 Minutes, before moving to lifestyle magazines Loaded and Attitude. He was a columnist for The Big Issue and landed a world exclusive with David Beckham that became the weekly magazine’s bestselling issue. He now writes regularly for The Guardian, The Telegraph, The Independent, Metro, FourFourTwo and the i new site. He is also the author of a number of non-fiction books.
-
'Epic meltdown'
Today's Newspapers A roundup of the headlines from the US front pages
By The Week Staff Published
-
The World of Tim Burton: a 'creepy, witty and visually ravishing' exhibition
The Week Recommends Sprawling show at the Design Museum features over 600 exhibits from across the directors' five-decade career from early sketches to costumes and props
By Irenie Forshaw, The Week UK Published
-
Crossword: October 31, 2024
The Week's daily crossword
By The Week Staff Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
Israel, UN agree to Gaza pauses for polio vaccinations
Speed Read Gaza's first case of polio in 25 years was confirmed last week in a 10-month-old boy who is now partially paralyzed
By Rafi Schwartz, The Week US Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published